Ergoteles’s Eton Pharmaceutcials ETON Stock Holding History

Ergoteles’s Portfolio ETON Stock Details ETON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50,500	Closed	-$311K	–	1344
2021 Q2	$311K	Buy	+50,500	New	+$374K	0.01%	1052

Other funds holding ETON

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ergoteles's ETON Position: Q3 2021 in Review

Ergoteles sold out of Eton Pharmaceutcials (ETON) in Q3 2021, closing a stake of 50,500 shares — an estimated $311K sold.

Ergoteles first reported a position in ETON in Q2 2021 and held it in 1 quarter. The position peaked at $311K in Q2 2021. 37 funds tracked by Wall St. Rank hold ETON as of Q3 2021.

Ergoteles reported no remaining Eton Pharmaceutcials position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 50,500 Eton Pharmaceutcials shares in Q3 2021, an estimated $311K.
Ergoteles first reported a position in Eton Pharmaceutcials in Q2 2021 and held it in 1 quarter.
Ergoteles's Eton Pharmaceutcials position peaked at $311K in Q2 2021.
37 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.